			Gilead Sc	iences EFPIA	Report - 20	023 Transfers	of value made	to HCPs and I	HCOs		Date of pul	blication: 30-06-2024
	Full Name	HCPs: City of Principal Practice / HCOs: City where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL		Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		
	(Art. 1.01)	(Art. 3)	(Schedule 1)	(Art. 3)	(Art. 3)	Donations and Grants to HCOs / (Art. 3.01.1.a)	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	TOTAL OPTIONAL
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate.											
HCPs	Bryndis Sigurdardottir	Reykjavik	Iceland	Reykjafold 4				107 072 kr	239 322 kr			346 394 kr
			OTHER,	NOT INCLUDED	ABOVE- (wher	e information can	not be disclosed on ar	n individual basis	for legal reason:	S		
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.02											
	Number of Recipients in aggregate disclosure - Art 3.02											
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02							0%	0%	0%	0%	0%
воэн	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate.											
	Landspitali University Hospital	Reykjavik	Iceland	Reykjafold 4						148 169 kr		148 169 kr
	OTHER, NOT INCLUDED ABOVE- (where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.02											
	Number of Recipients in aggregate disclosure - Art 3.02											
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02					0%	0%	0%	0%	0%	0%	0%
R&D						AGGREGATE D	DISCLOSURE					
	Transfers of Value re Research & Development as defined in Article 3.04 and Schedule 1										0 kr	494 563 kr